Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2020

View Archived Issues

In AML, collapse prevents relapse

Notable responses seen in COVID-19 patients with respiratory failure given RLF-100

Daiichi Sankyo describes new SIRT6 activators

G protein-coupled receptor 35 modulators discovered at Precision IBD

Novartis presents NLRP3 inflammasome inhibitors

Merck KGaA discovers dual adenosine A2A/A2B receptor antagonists

Discovery and preclinical evaluation of anticancer agent, PVHD-303

First-in-human data presented for [68Ga]P15-041 radiotracer

Yumanity Therapeutics identifies stearoyl-CoA desaturase 1/5 inhibitors

VBL announces second successful pre-planned interim analysis of the phase III OVAL study

First patient enrolled in phase III InPedILD study of nintedanib

FDA approves Viltepso for the treatment of DMD in patients amenable to exon 53 skipping therapy

First phase I study of ATG-017 approved in Australia

Recombinant SARS-CoV-2 S1-Fc fusion protein shows promise in animal species

Treadwell initiates phase II study of CFI-400945 and durvalumab in TNBC

TREM2 targeting can synergize with checkpoint blockade

Phase I study results support further evaluation of yellow fever monoclonal antibody TY-014

Bio-Path begins dosing in amended stage 2 of phase II prexigebersen study in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...